	US 11,952,409 B2
	*Amidated peptides and their deamidated counterparts displayed by non-HLA-A02 for use in immunotherapy against different types of cancers preliminary class**
Jens Hukelmann, Tuebingen (DE); Heiko Schuster, Tuebingen (DE); Lena Wullkopf, Tuebingen (DE); Christoph Schraeder, Tuebingen (DE); Jens Fritsche, Tuebingen (DE); Daniel Johannes Kowalewski, Tuebingen (DE); Michael Roemer, Tuebingen (DE); and Oliver Schoor, Tuebingen (DE)
Assigned to IMMATICS BIOTECHNOLOGIES GMBH, Tuebingen (DE)
Filed by Immatics Biotechnologies GmbH, Tuebingen (DE)
Filed on Apr. 24, 2023, as Appl. No. 18/305,928.
Application 18/305,928 is a division of application No. 17/489,446, filed on Sep. 29, 2021.
Claims priority of provisional application 63/223,291, filed on Jul. 19, 2021.
Claims priority of provisional application 63/084,919, filed on Sep. 29, 2020.
Prior Publication US 2023/0257442 A1, Aug. 17, 2023
Int. Cl. C07K 14/725 (2006.01); A61K 35/17 (2015.01); A61K 38/00 (2006.01); C07K 14/74 (2006.01); C07K 16/28 (2006.01)

CPC C07K 14/7051 (2013.01) [A61K 35/17 (2013.01); C07K 14/70539 (2013.01); C07K 16/2833 (2013.01); A61K 38/00 (2013.01); C07K 2319/30 (2013.01)]

20 Claims

1. A method of treating a patient who has cancer, comprising administering to said patient a population of activated T cells that kill cancer cells that present a peptide consisting of the amino acid sequence of IYLDRTLLTTI (SEQ ID NO: 56), wherein the cancer is non-small cell lung cancer adenocarcinoma (NSCLCadeno), squamous cell non-small cell lung cancer (NSCLCsquam), head and neck squamous cell carcinoma (HNSCC), gallbladder cancer (GBC), renal cell carcinoma (RCC), NSCLC samples that could not unambiguously be assigned to NSCLCadeno or NSCLCsquam (NSCLCother), esophageal cancer (OSCAR), gastric cancer (GC), uterine endometrial cancer (UEC), small cell lung cancer (SCLC), melanoma (MEL), hepatocellular carcinoma (HCC), and cholangiocellular carcinoma (CCC).